OXYGENTA PHARMACEUTICAL LIMITE (OXYGENTAPH.BO)
INR 75.3
(0.61%)
INR 75.3
(0.61%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -1.04 INR | 87.24% |
| 2022 | -8.15 INR | -1795.35% |
| 2021 | -0.43 INR | -114.98% |
| 2020 | 2.87 INR | 150.62% |
| 2019 | -5.67 INR | -77.74% |
| 2018 | -3.19 INR | 28.15% |
| 2017 | -4.44 INR | 21.97% |
| 2016 | -5.69 INR | -5.57% |
| 2015 | -5.39 INR | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q1 | -0.39 INR | -115.29% |
| 2023 FY | - INR | 87.24% |
| 2023 Q1 | -1.36 INR | 54.97% |
| 2023 Q2 | -0.94 INR | 30.88% |
| 2023 Q3 | -1.00 INR | -6.38% |
| 2023 Q4 | 2.55 INR | 355.0% |
| 2022 Q2 | -1.64 INR | -37.82% |
| 2022 FY | - INR | -1795.35% |
| 2022 Q1 | -1.19 INR | -85.94% |
| 2022 Q4 | -3.02 INR | -31.88% |
| 2022 Q3 | -2.29 INR | -39.63% |
| 2021 Q3 | 0.15 INR | 155.56% |
| 2021 Q4 | -0.64 INR | -526.67% |
| 2021 Q2 | -0.27 INR | -158.7% |
| 2021 FY | - INR | -114.98% |
| 2021 Q1 | 0.46 INR | -41.77% |
| 2020 Q4 | 0.79 INR | -72.28% |
| 2020 FY | - INR | 150.62% |
| 2020 Q3 | 2.85 INR | 0.0% |
| 2019 FY | - INR | -77.74% |
| 2018 FY | - INR | 28.15% |
| 2017 FY | - INR | 21.97% |
| 2016 FY | - INR | -5.57% |
| 2015 FY | - INR | 0.0% |